Market capitalization | $248.03b |
Enterprise Value | $271.59b |
P/E (TTM) P/E ratio | 20.54 |
EV/FCF (TTM) EV/FCF | 18.30 |
EV/Sales (TTM) EV/Sales | 4.32 |
P/S ratio (TTM) P/S ratio | 3.94 |
P/B ratio (TTM) P/B ratio | 5.58 |
Dividend yield | 3.18% |
Last dividend (FY24) | $3.12 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
26 Analysts have issued a Merck & Co. forecast:
26 Analysts have issued a Merck & Co. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 62,893 62,893 |
8%
8%
|
|
Gross Profit | 45,928 45,928 |
12%
12%
|
|
EBITDA | 18,665 18,665 |
58%
58%
|
EBIT (Operating Income) EBIT | 14,467 14,467 |
80%
80%
|
Net Profit | 12,148 12,148 |
164%
164%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Head office | United States |
CEO | Robert Davis |
Employees | 72,000 |
Founded | 1891 |
Website | www.merck.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.